Skip to main content
OpenTrials
Completed

NCT Number: NCT01420159

Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Minor Trauma

This study investigates the treatment of acute pain, an unpleasant feeling caused by an injury. The overall purpose of the study is to gain more information that the pain relief medicine Penthrox(Methoxyflurane) administered using the Penthrox Inhaler(a distinctive green, whistle like object that you breathe through) is safe and works at relieving pain in patients aged 12 years and older who are admitted to a hospital Emergency Department with a minor injury (known as trauma).

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Barnsley District General Hospital, Barnsley, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients 12 years of age or older who are able to give written informed consent or who are accompanied by a parent(s)/legal guardian able to provide written informed consent on their behalf.
  • Evidence of signed and dated informed consent document(s) indicating that the patient (and/or a parent/legal guardian) has been informed of all pertinent aspects of the study.
  • Pain Score ≥ 4 to ≤ 7 as measured using Numerical Rating Scale (NRS) at the time of admission, due to minor trauma.

Exclusion criteria

  • Life-threatening condition requiring immediate admission in the Operating Room or Intensive Care Unit.
  • Presence of any other clinical condition(s) that may, in the opinion of the investigator, impact on the patient's ability to participate in the study, or on the study results, including history of head injury and/or altered consciousness.
  • Unable to provide written informed consent.
  • Known pregnancy or lactation
  • Acute intoxication with drugs or alcohol, based on the judgement of the attending physician.
  • Treatment with any analgesic agent within 5 hours prior to presentation to ED (except diclofenac sodium which is prohibited within 8 hours prior to presentation to ED).
  • Current ongoing use of analgesics for chronic pain.
  • Use of an investigational product within one month prior to presentation to ED.
  • Known personal or familial hypersensitivity to fluorinated anaesthetics.
  • Known personal or familial history of malignant hyperthermia.
  • Clinically significant respiratory depression.
  • Use of methoxyflurane in the previous 4 weeks.
  • Known pre-existing clinically significant renal or hepatic impairment according to the judgement of the clinician.
  • Clinically significant cardiovascular instability.

Treatment and study plan

Methoxyflurane

Drug

Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.

Other names: Penthrox

Primary outcomes

  1. VAS Score

    Time frame: Twenty Minutes

    The difference between treatment and placebo on the VAS pain score

Secondary outcomes

  1. Rescue Medication

    Time frame: Up to a maximum of 6 hours

    A request for rescue medication, time of request for rescue medication and the quantity of opioid equivalent rescue medication administered will be measured

  2. Time to pain relief

    Time frame: Up to a maximum of 6 hours

    The number of inhalations of study treatment until pain relief is achieved and the time until pain relief is achieved.

  3. Responder analysis

    Time frame: Up to a maximum of 6 hours

    The number of responders will be defined

  4. Safety Analysis

    Time frame: Up to 16 days

    Evaluation of Adverse Events experienced during treatment. Evaluation of Adverse Events, including safety laboratory samples, up to 14 +/- 2 days following Emergency Department discharge

Sponsors and collaborators

Lead sponsor

Medical Developments International Limited

Industry

Collaborators

  • ORION Clinical Services

Registry information

Official study title

A Randomised, Double Blind, Multi-centre, Placebo Controlled Study to Evaluate the Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Patients Presenting to an Emergency Department With Minor Trauma

Acronym: STOP!

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Aug 19, 2011
Registry last updated
Oct 31, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.